Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
Abstract Background PCSK9 regulates low-density lipoprotein cholesterol (LDLc) level and has been implicated in hypercholesterolemia. Aberrant plasma lipid profile is often associated with various cancers. Clinically, the relationship between altered serum lipid level and hepatocellular carcinoma (H...
Main Authors: | Dipti Athavale, Surbhi Chouhan, Vimal Pandey, Shyamananda Singh Mayengbam, Snahlata Singh, Manoj Kumar Bhat |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-10-01
|
Series: | Cancer & Metabolism |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40170-018-0187-2 |
Similar Items
-
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
by: A. A. Shikaleva, et al.
Published: (2021-01-01) -
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
by: Emma M. O’Connell, et al.
Published: (2020-06-01) -
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
by: Vittoria Cammisotto, et al.
Published: (2022-03-01) -
THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
by: Алексей Михайлович Чаулин, et al.
Published: (2019-12-01) -
The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process – is there a link?
by: Malwina Grobelna, et al.
Published: (2019-10-01)